

青少年(年)避孕指引

前言

青少年(年)泛指 13-19¹ 歲的年輕族群，乃處於生理與心理急遽變化的階段，是人生發展到成年過程中的重要時期。近年來台灣青少年(年)的第一次性行為年齡逐漸提早，高中職階段的性行為比率有逐年增加的趨勢，青少年(年)較容易在發生性行為時卻未想到可能面臨懷孕、墮胎或感染性傳染疾病等風險。因此，如何讓青少年(年)正確尋求相關訊息，獲得諮詢與協助就相當重要。

根據一項全球調查，在與新伴侶的性行為過程中，亞太地區的青少年有 48% 沒有使用避孕方式，且避孕資訊有 56% 來源為網站和部落格、39% 來自於聊天室或論壇²；而 31% 的台灣年輕女性在初次性行為時未使用任何避孕方式³；諸多統計數字都令人擔憂，且此時其心理上或經濟上最不能承擔意外懷孕的風險。

因此如何務實看待並了解青少年(年)的需求與心態，讓他們擁有正確的性知識、態度與避孕觀念，以保護他們不要曝露在意外懷孕及其後續帶來的健康風險和心理壓力中，是一門相當重要的議題。

台灣婦產科醫學會認為在青少年(年)階段不要有性行為是最有效避免懷孕和感染到性傳染疾病的方法，但萬一無法避免性行為時，台灣婦產科醫學會建議的避孕方式為” 雙重防護法”；即女生使用口服避孕藥，男生使用保險套，此方法可同時有效避孕及預防性傳染疾病。

重點訊息：

1. 口服避孕藥：

- 作用機轉⁴：
 - ◆ 抑制排卵。
 - ◆ 干擾子宮內膜的生長，抑制胚胎的著床。
 - ◆ 增加子宮頸黏液濃稠度，使精子不易通過。
- 使用後意外懷孕率：正確使用口服避孕藥的失敗率小於 1%^{5,19,41}。
- 優點：
 - ◆ 女性可自主決定並使用的避孕措施。
 - ◆ 使用期間會有規則月經及改善經痛^{6,47}，降低經血過多所導致缺鐵性貧血^{10,39}。
 - ◆ 治療青春痘^{10,22,24,39}(部份具有抗雄性化的口服避孕藥，如：含有黃體素 Cyproterone acetate (CPA)，或第四代黃體素 Drospirenone (DRSP)之口服避孕藥)，與多毛症¹¹(部份具有抗雄性化的口服避孕藥，如：含有黃體素 CPA 之口服避孕藥)。

- ◆ 改善經前症候群^{8,10,25,26}(部份含有第四代黃體素 DRSP 搭配 24+4 劑型的口服避孕藥；88%受試者生理與心理情緒與參加試驗時相同或是有改善。)
- ◆ 改善多囊性卵巢症候群^{23,27} (部份具有抗雄性化的口服避孕藥，如：含有黃體素 CPA 之口服避孕藥)。
- ◆ 改善因子宮肌瘤造成的疼痛與出血¹⁰。
- ◆ 降低(功能性)卵巢囊腫的發生率¹²。
- ◆ 長期使用降低乳房纖維腺瘤和纖維囊腫疾病的發生率^{7,10,21,47,50}。
- ◆ 降低卵巢癌發生率約 29-50%^{9,14,18,28,29,30,35,40}。
- ◆ 降低子宮內膜癌發生風險 25-90%^{18,31,32,33,34,35}。
- ◆ 降低子宮癌發生率 42%-70%^{14,18}。
- ◆ 降低大腸直腸癌發生率 19-50%^{10,14,36,37}。
- ◆ 降低骨盆腔發炎機率約 78%^{15,38,39}。
- ◆ 降低約 90%子宮外孕的風險³⁹。

● 注意事項：

- ◆ 初經來潮後即可使用口服避孕藥⁵。
- ◆ 使用口服避孕藥並不會造成停藥後的不孕¹⁸。
- ◆ 依目前研究顯示使用低劑量口服避孕藥並不會增加乳癌的風險^{13,14,18,48,49}。
- ◆ 少數人在服用初期會有點狀出血症狀¹⁶；頭暈、噁心(使用劑量較低的口服避孕藥可減少此症狀)¹⁶；體重增加(部份新型口服避孕藥可改善此症狀)²²。
- ◆ 這些可能的症狀與荷爾蒙的關係如下^{51,52}：

Estrogen Excess	Estrogen Deficiency	Progesterone Excess	Progesterone Deficiency
<ul style="list-style-type: none"> • Nausea/ Bloating • Cervical mucorrhea • Melasma/ Chloasma • Hypertension • Migraine Headache • Breast fullness, tenderness • Edema • Deep Vein 	<ul style="list-style-type: none"> • Early/ Midcycle BTB* • Hypomenorrhea 	<ul style="list-style-type: none"> • Increase appetite • Weight gain • Tiredness, fatigue • Hypomenorrhea • Acne, oily scalp • Hair loss or Hirsutism • Depression • Vaginal yeast infections 	<ul style="list-style-type: none"> • Late BTB** • Amenorrhea • Hypermenorrhea

Thrombosis(DVT)		• Breast regression	
• Cerebral Vascular Accident(CVA)		• Hypertension	

*Early to midcycle break through bleeding occurs days 1-14 of the cycle (or menses never stops completely)

**Late break through bleeding occurs after day 14 of the cycle


◆ 若有下表中列出之狀況，建議使用含較低劑量雌激素的口避孕藥^{51,52}：

Exception/Problem	Appropriate Product(s)
40-50 y/o; need to minimize risk of thrombosis; poorly controlled diabetes; heavy smoker; perimenopausal	Loestrin™ 1/20, Alesse™
Nausea, breast tenderness, vascular headaches, leucorrhea, hypermenorrhea, chloasma, hypertension, visual changes	Levlen™, Nordette™, Lo/Ovral™, Low Ogestrel™, Cyclessa™, Yasmin™
Spotting, BTB*, dysmenorrhea	Levlen™, Nordette™, Lo/Ovral™, Low Ogestrel™, Desogen™, Apri™, Ortho-Cept™, Ortho-Cyclen™
Acne, hirsutism, oily skin, sebaceous cysts, weight gain	Desogen™, Ortho-Cept™, Ortho-Cyclen™, Ortho-TriCyclen™, Ovcon™-35, Brevicon™, Modicon™, Cyclessa™, Yasmin™
Family history of atherosclerotic cardiovascular disease (for more favorable lipid profile)	Desogen™, Ortho-Cept™, Ortho-Cyclen™, Ortho-TriCyclen™, Ovcon™-35, Brevicon™, Modicon™, Cyclessa™, Yasmin™
Gallbladder disease (need decreased estrogen/progesterone)	Loestrin™ 1/20, Alesse™
Seizure history (OC's increase incidence of seizures) Also, seizure medications (except felbamate, gabapentin, & valproic acid) induce metabolism of estrogen & possibly progesterone causing BTB*, spotting, & pregnancy	A. Progestin only (Depo-Provera™ or Norplant™ only) B. Higher estrogen content COC (Demulen™ 1/50, Ovra™, Ovcon™-50)
History of CVA, ischemic heart disease, uncontrolled hypertension, Type 1 DM with vascular disease, migraine due to estrogen, current liver disease (tumor, impairment), current	Progestin-only product (mini-pills, injection, implantable)


DVT, smoker > 35y/o, breast feeding, sickle cell anemia	
---	--

*BTB=Break Through Bleeding

- ◆ 可能會些微增加靜脈血栓的風險¹⁶，使用較低劑量的口服避孕藥可減少此風險，且風險更低於懷孕或產後婦女，無其他禁忌症之女性在諮詢後可安心使用。其風險數據請參考以下表格：
Absolute VTE rate in reproductive age women⁴²⁻⁴⁶



- ◆ 靜脈血栓風險在服用口服避孕藥後 3-6 個月即大幅下降，因此除非有特殊原因，不建議反覆的停藥¹⁷。



Venous thromboembolism (VTE) risk over time following start of combined oral contraceptive use. Original figure derived from data in Reference 8. WY, woman-years.

- ◆ 以下藥物會與口服避孕藥有交互作用^{51,52}：

Interaction Drug	Problem
Drugs which decrease COC enterohepatic	Spotting, BTB*, Pregnancy

recirculation Ampicillin, Penicillin, Cephalosporin, Chloramphenicol, Dapsone, Erythromycin, Isoniazid, Sulfonamides, Tetracycline, TMP/SMZ –(Bactrim™, Septra™)	
Drugs which induce COC Metabolism Barbiturates (Phenobarbitol), Carbamazepine (Tegreto™), Ethosuxamide, Griseofulvin, Phenytoin, Rifampin, St. John's Wort, Felbamate, Nelvinafir	Spotting, BTB*, Pregnancy
Cyclosporine	Doubling of cyclosporine level
Atorvastatin (Lipitor™)	Enhanced levels of COC's
Anticoagulants (i.e. Coumadin™)	Decrease anticoagulant response
Benzodiazepines (i.e. Valium™, et. al.)	Enhanced benzodiazepine response
Phenytoin (Dilantin™)	Increased phenytoin levels
Prednisolone, Theophylline, Topiramate (Topamax™)	Decreased liver clearance of COC
Insulin	Decrease insulin efficiency

*BTB=Break Through Bleeding

◆ **常見禁忌症**²⁰ (詳細禁忌症請詳閱使用藥物仿單說明) :

Contraindication to combined hormonal contraceptives	
Absolute contraindications (class 4 in the WHO classification)	Relative Contraindications (class 2 or 3 in the WHO classification)
<ul style="list-style-type: none"> • Pregnancy • Undiagnosed genital bleeding • Breast Cancer • Past of present circulation disease (for example, arterial or venous thrombosis, ischemic heart disease, and cerebral hemorrhage) • Thrombophilia • Pill induced hypertension • Migraine with aura • Active liver disease, cholestatic jaundice, Dubin-Johnson syndrome, acute porphyria • Systemic lupus erythematosus • Haemolytic-uraemic syndrome 	<ul style="list-style-type: none"> • Smoker aged over 35 years • Hypertension (blood pressure above 140/90 mmHg) • Diabetes • Hyperprolactinaemia • Gall bladder disease • Migraine without aura • Otosclerosis • Sickle cell disease

- | | |
|---|--|
| <ul style="list-style-type: none">• Thrombotic thrombocytopenic purpura | |
|---|--|

2. 保險套：

- 作用機轉：利用物理阻隔的方式，阻止精子進入陰道、子宮。
- 一般使用保險套意外懷孕率約 15%⁵。
- 優點：可同時降低性傳染疾病。
- 缺點：
 - ◆ 避孕效果不如口服避孕藥。
 - ◆ 保險套上之潤滑劑可能使陰道產生過敏現象。
- 注意事項：
 - ◆ 對乳膠材質過敏者不適用。
 - ◆ 購買或使用前先確定包裝完整，使用日期仍在有效期限內。
 - ◆ 每次性行為都必須全程使用，不可有僥倖心態。
 - ◆ 陰莖一勃起就必須戴上保險套，且需檢查是否戴好，記得要一直待到陰莖根部。
 - ◆ 避免使用油性潤滑劑或是其他會影響保險套材質潤滑劑，建議使用水性潤滑劑。
 - ◆ 每個保險套只能使用一次，如果發現戴反了，不要翻面使用，立即更新。
 - ◆ 射精後應立刻取出保險套。
 - ◆ 事後記得檢查，若有不慎或使用不當，要趕快採取預防措施。
 - ◆ 未用過的保險套要保存在乾燥、涼爽地方，以免濕度、溫度影響保險套品質。

說明：

根據調查，青少女(年)有健康疑問(包含避孕)時，網路乃其主要訊息來源，其後依序為父母、同學或朋友、與電視節目，雖然有五成五青少女認為醫師是可信賴的資訊來源，但僅有不到一成會實際向婦產科醫師諮詢，有相當大的落差。台灣婦產科醫學會建議，父母應於青少女初經來潮後，儘快陪伴她們到婦產科醫院或診所諮詢。

備註：

- 性交中斷法與安全期計算法未納入考量，因其不屬於高效避孕措施。
- 事後避孕藥僅供緊急使用，不屬於常規避孕方式。由於避孕效果較差，且有時效性，建議青少年(年)萬一需要時需向婦產科專科醫師諮詢。
- 本指引乃供臨床參考，實際案例請依個案判斷。
- 若有藥物不良反應發生，請聯絡以下通報窗口：
衛生署藥物不良反應通報中心 地址：台北市中正區愛國東路 100 號
電話：(02) 2370-1704 傳真：(02)2370-1711 網址：<http://www.adr.doh.gov.tw>
- 請注意，根據中華民國法律，與未滿十六歲者進行性行為將觸犯刑法。
- 醫師在處方避孕藥前，可多了解病患的狀況建議適合的避孕方式。

Considerations for Contraceptive Recommendations*	
Menstrual History	Age of menarche (onset of periods) Date of LMP* Duration of average menses Regularity Cycle length Spotting or BTB** Incidence and type of PMS or PMT** Hormonal sensitivity
Contraceptive History	Previous Use Response Side effects Compliance
Routine Physical Examination	Blood pressure Breast exam Pelvic exam Pap smear Liver function evaluation Family history Social history

* Last menstrual period

** Break through bleeding

*** Premenstrual syndrome or Premenstrual Tension

- 各種避孕方式的失敗率可參考下表⁵:

Method	% of women experience an unintended pregnancy within the first year of use		% of women continuing use at one year
	Typical use	Perfect use	
No method	85	85	
Spermicides	29	18	42
Withdrawal	27	4	43
Fertility awareness-based methods	25		
Standard days method [†]		5	
Two day method*		4	
Ovulation method [†]		3	
Sponge			
Parous women	32	20	46
Nulliparous women	16	9	57
Diaphragm**			
Condom***			
Female(Reality)	21	5	49
Male	15	2	53
Combined pill and Progestogen-only pill	8	0.3	68
Evra patch	8	0.3	68
NuvaRing	8	0.3	68
Depo-Provera	3	0.3	56
Combined injectable (Lunelle)	3	0.05	56
IUD			
ParaGard (cooper T)	0.8	0.6	78
Mirena (LNG-IUS)	0.2	0.2	80
Implanon	0.05	0.05	84
Female sterilization	0.5	0.5	100
Male sterilization	0.15	0.1	100

參考文獻:

1. United Nations. (<http://social.un.org/index/Youth/FAQs.aspx>)
Definition: Youth-15~24yrs. Teenagers-13~19yrs. Young adult-20~24yrs.
2. WCD survey 2011; Clueless or Clued up: Your Right to be informed about contraception survey. Fieldwork carried out by GFK Healthcare. April-May 2011. p.9 & p.42.
3. TNS survey 2011. p.11.
4. Wiegratz I, Thaler CJ. Hormonal contraception--what kind, when, and for whom? Dtsch Arztebl Int 2011;108:495-506.

5. Medical eligibility criteria for contraceptive use, Fourth Edition 2009, WHO.
6. Bitzer J. The added benefits of contraception. *Gynaecology Forum* 2009;14:3.
7. Howard Ory, et al. Oral Contraceptives and Reduced Risk of Benign Breast Diseases, *N Engl J Med* 1976;294:419-422.
8. Bachmann G, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. *Contraception* 2004;70:191-198.
9. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. *Lancet* 2008;371:303-314.
10. Maguire K, Westhoff C. The state of hormonal contraception today: established and emerging noncontraceptive health benefits. *Am J Obstet Gynecol* 2011;205(Suppl 4):S4-8.
11. Oner G, Muderris II. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism. *Contraception* 2011;84:508-511.
12. Vessey MP, Metcalfe A, Wells C, et al. Ovarian neoplasm, functional ovarian cysts and oral contraceptives. *Br Med J* 1987;294: 1518 -1520.
13. Marchbanks PA, et al. Oral contraceptives and the risk of breast cancer. *N Engl J Med* 2002; 346:2025-2032.
14. Vessey M, Painter R. Oral contraceptive use and cancer. Finding in a large cohort study, 1968-2004. *Br J Cancer* 2006;95:385-389. Epub 2006 Jul 4.
15. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. *Obstet Gynecol* 1991;77:261-264.
16. Spencer AL, Bonnama R, McNamara MC. Helping women choose appropriate hormonal contraception: update on risks, benefits, and indications. *Am J Med* 2009;122:497-506.
17. Klaas Heinemann, Lothar A J Heinemann. Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel. *J Fam Plann Reprod Health Care* 2011;37:132-135; doi:10.1136/jfprhc-2011-14524
18. Hannaford PC, et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. *Br Med J* 2007;335:651.
19. Hernádi L, et al. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. *Contraception* 2009;80:18-24
20. Amy JJ, Tripathi V. Contraception for women: an evidence based overview *Br Med J* 2009; 339:563-568.
21. Rohan TE, Miller AB. A cohort study of oral contraceptive use and risk of benign breast disease. *Int J Cancer* 1999; 82:191-196.
22. Pitashny M, et al. Oral contraceptives: their mode of action and dermatologic applications. *Skinmed* 2005;4:101-106.
23. J.Vrbi'kova', D.Cibula. Combined oral contraceptives in the treatment of polycystic ovary syndrome. *Hum Reprod Update* 2005;11:277-291
24. Arowojolu AO, et al. Combined oral contraceptive pills for treatment of acne. *Cochrane Database Syst Rev*

2012;7:CD004425.

25. Yonkers KA, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. *Obstet Gynecol*.2005;106:492-501
26. Pearlstein TB, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. *Contraception*.2005;72:414-421.
27. Functional Ovarian Cysts and Oral Contraceptives: Negative Association Confirmed Surgically. *JAMA* 1974;228:68-69.
28. Ness RB, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. *Steroid Hormones and Reproductions*. *Am J Epidemiol* 2000;152:233-241.
29. Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. *Eur J Cancer* 2010;46:2275-2284.
30. Roberta B. Ness, et al. Contraception Methods, beyond Oral Contraceptives and Tubal Ligation, and Risk of Ovarian Cancer. *Ann Epidemiol* 2011;21:188–196.
31. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. *JAMA* 1987;257:796-800.
32. Kaufman DW, et al. Decreased risk of endometrial cancer among oral-contraceptive users. *N Engl J Med* 1980; 303:1045-1047.
33. Hulka BS, et al. Protection against endometrial carcinoma by combination-product oral contraceptives. *JAMA* 1982;247:475-477.
34. Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. *Obstet Gynecol* 1993;82:931-935.
35. Cibula D, et al. Hormonal contraception and risk of cancer. *Hum Reprod Update* 2010;16:631-650.
36. Bosetti C, et al. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. *Hum Reprod Update* 2009;15:489-498.
37. Fernandez E, et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. *Br J Cancer* 2001;84:722-727.
38. Wølner-Hanssen P, et al. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. *JAMA* 1990;263:54-59.
39. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. *Am J Obstet Gynecol* 2004;190(Suppl 4):S5-22.
40. Shelley S. Tworoger, et al. Association of Oral Contraceptive Use, Other Contraceptive Methods, and Infertility with Ovarian Cancer Risk. *Am J Epidemiol* 2007;166:894–901.
41. Dinger J, et al. Effectiveness of oral contraceptive pills in a large US cohort comparing progestogen and regimen. *Obstet Gynecol* 2011;117:33-40
42. US Prescribing Information for Combination Oral Contraceptives (YAZ) 2012.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021676s012lbl.pdf
43. Heit JA, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. *Ann Intern Med* 2005;143: 697-706
44. Dinger JC, et al. The safety of a drospirenone-containing oral contraceptive final results from the European

Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. *Contraception* 2007;75: 344-354

45. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. *Contraception* 2007;75:328-336
46. Practice bulletin no. 123: Thromboembolism in pregnancy. *Obstet Gynecol* 2011;118:718-729
47. Guillebaud J. *Contraception Today*, seventh edition, 2012. p.15.
48. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. *Lancet* 1996;347:1713-1727.
49. Kahlenborn C, et al. Oral contraceptive use as a risk factor for premenopausal breast cancer: a metaanalysis. *Mayo Clin Proc* 2006; 81:1290-1302.
50. Martin V, David Y. Oral contraceptives and benign breast disease: an update of findings in a large cohort study. *Contraception* 2007;76:418–424
51. Bucci KK, Carson DS. Contraception. In: DiPiro JT, Talbert JL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. *Pharmacotherapy: A Pathophysiologic Approach*. Fourth Edition. Stamford: Appleton and Lange, 1999:1327-1341.
52. Ruggiero RJ. Contraception. In: Koda-Kimble MA, YoungLY, eds. *Applied Therapeutics: The Clinical Use of Drugs*. Seventh Edition. Philadelphia: Lippincott Williams & Wilkins. 2001;43:1-43:23.